Clinical Trials Browser

Interventional × Urinary Bladder Neoplasms × cabozantinib × Clear all

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-04-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Phase 1 Active not recruiting

152 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05092958 2026-04-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

654 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04289779 2024-12-04

ABATE

Phase 2 Active not recruiting

46 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT03824691 2021-02-25

ARCADIA

Phase 2 Unknown

122 enrolled

Genitourinary

Urinary Bladder Neoplasms